Neuroene Therapeutics

Executive Summary

Neuroene Therapeutics is a private, preclinical-stage biotechnology company developing novel small molecule therapies based on Vitamin K analogs to address neurological diseases driven by mitochondrial dysfunction. Founded in 2018 and headquartered in Cambridge, USA, the company's lead programs target medication-resistant epilepsy and Parkinson's disease, with expansion potential into rare mitochondrial disorders and public health emergencies. By leveraging the neuroprotective properties of Vitamin K derivatives, Neuroene aims to restore mitochondrial function and reduce oxidative stress, offering a differentiated approach to diseases with high unmet medical need. The company is currently in preclinical development and has not yet initiated clinical trials. While the scientific rationale is compelling and the target indications represent large markets, Neuroene faces typical early-stage risks including translational uncertainty, funding requirements, and regulatory hurdles. Conviction is moderate given the absence of publicly disclosed in vivo efficacy data or financing details. Key upcoming catalysts include completion of IND-enabling studies, potential Series A financing, and initial clinical data readouts. Success in these milestones could validate the platform and position Neuroene for further development or partnership opportunities.

Upcoming Catalysts (preview)

• Q3 2026Completion of IND-enabling studies65% success
• Q4 2026Series A financing round70% success
• Q3 2026Presentation of preclinical efficacy data in epilepsy models80% success